Full-Time

Field Reimbursement Manager

West

Posted on 4/1/2026

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

Compensation Overview

$152k - $202k/yr

+ Annual Short-Term Incentive + Annual Long-Term Incentive + Equity

San Francisco, CA, USA + 1 more

More locations: Los Angeles, CA, USA

Hybrid

Category
Growth & Marketing (1)
Requirements
  • Bachelor's Degree
  • 8+ years of experience in pharmaceutical or biotechnology, with experience in Market Access, Payer Account Management, and/or Access and Reimbursement
  • Capability to develop strategic account plans and oversee contract performance to ensure ongoing business health
  • Proven track record of success, meeting or exceeding business KPIs
  • Working knowledge of the formulary inclusion process and familiarity with sub-committees
  • Analytical mindset with the ability to interpret sales data, market trends, and customer insights
  • Experience working in CRM systems and sales analytics tools
  • Ability to travel as required approximately 60% of the time to meet with customers and attend industry events
Responsibilities
  • Proactively address patient access barriers by working with customers and accounts to resolve complex reimbursement issues, including prior authorizations, appeals, and denials
  • Educate private practices, multi-specialty groups, facilities, and their staff on reimbursement support programs, coverage, coding, and payer policies
  • Accountable for ensuring access barriers are minimized, for appropriate patients, to obtain Invivyd products through health care professional education
  • Have a thorough understanding of payor policies and navigating the coverage landscape
  • Deliver clear and actionable information to practice managers, billing staff, nurses, and reimbursement teams to improve their understanding of payer policies and processes
  • Conduct regular reviews with practices to understand their utilization of reimbursement support services and recommend program enhancements based on customer needs
  • Report payor trends related to approved products to Patient Services and Market Access account management teams
  • Have a deep understanding of coverage pathways to access, for both medical and pharmacy benefit products
  • Have a deep understanding of the Medicare reimbursement landscape
  • Provide expertise within the national/regional payor landscape in order to educate providers on navigating the reimbursement process and payer trends
  • Provide training to healthcare professionals on the drug reimbursement process, coding, and billing practices
  • Navigate and manage access and reimbursement concerns by pulling in the appropriate Invivyd stakeholder
  • Stay informed about relevant business trends, competitive landscape, regulatory changes, and healthcare policy developments that may impact our customers
  • Leverage market insights to anticipate customer needs and develop strategies that maintain a competitive edge
  • Exhibit executive presence to provide presentations on insights and trends to commercial and executive leadership
  • Ensure that all activities and interactions adhere to relevant pharmaceutical regulations, industry standards, and ethical guidelines

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Your Connections

People at Invivyd who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PEMGARDA Q1 2026 revenue reached $13.7 million, up 22% year over year.
  • VYD2311 reached full enrollment in March 2026, with Q3 2026 data expected.
  • Cash of $184.2 million, plus April ATM proceeds, funds near-term development.

What critics are saying

  • VYD2311 depends on circulating variants at readout, making efficacy highly path-dependent.
  • COVID attack rates already slowed recruitment, threatening a commercial non-event.
  • Pipeline sprawl across measles, RSV, Lyme, and long COVID dilutes capital and focus.

What makes Invivyd unique

  • Invivyd combines evolutionary virology, predictive modeling, and antibody engineering.
  • PEMGARDA, pemivibart, won FDA EUA in March 2024 for COVID prophylaxis.
  • Michael Mina’s CMO appointment strengthens infectious-disease credibility and public-health positioning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-6%

2 year growth

-3%
Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

TipRanks
Nov 17th, 2025
Invivyd Announces Common Stock Offering

Invivyd announced an underwritten public offering of its common stock, with all shares offered by the company. The proceeds will be used for commercial preparedness for VYD2311, R&D for pipeline programs like respiratory syncytial virus and measles, advancement of the SPEAR Study Group on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and general corporate purposes. Cantor is the sole book-running manager for the offering.

Stock Titan
Aug 22nd, 2025
Invivyd Closes $57.5M Public Offering

Invivyd has announced the successful closing of a public offering, raising $57.5 million. The underwriter also fully exercised their option to purchase additional shares.

INACTIVE